SB27 PK data sharpens the pembrolizumab biosimilar race

As Keytruda's patent cliff draws closer, Samsung Bioepis has moved SB27 past a critical early threshold, pharmacokinetic bioequivalence in a multicountry Phase 1 study, adding measurable weight to an oncology biosimilar pipeline that CMC and regulatory teams are watching closely.

SB27 meets Phase 1 PK bioequivalence in NSCLC patients

Samsung Bioepis announced that SB27, its proposed biosimilar to pembrolizumab (Keytruda), demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study conducted in patients with non-small cell lung cancer. The study design, using an active patient population rather than healthy volunteers, reflects the clinical complexity inherent to high-potency oncology biologics, where ethical and physiological constraints shape PK trial architecture.

PK bioequivalence is a foundational comparability endpoint under ICH Q5E and relevant biosimilar guidance from both FDA and EMA. Meeting this endpoint does not confirm full biosimilarity; it establishes the PK bridge required before confirmatory efficacy and safety studies can proceed. The data positions SB27 to advance into later-stage clinical evaluation, though no Phase 3 timeline has been disclosed.

The analytical comparability read for oncology biosimilar teams

Pembrolizumab is a high-complexity PD-1 inhibitor, and its biosimilar development carries a demanding analytical comparability burden. Structural characterisation, binding assays, and functional equivalence data must collectively support the totality-of-evidence package regulators expect under 21 CFR Part 601 and EMA's biosimilar framework. PK alignment in NSCLC patients strengthens that package, but CMC teams will note that immunogenicity profiling and Fc-mediated effector function comparability remain critical open items at this stage.

For QA directors at biosimilar manufacturing sites, the NSCLC patient population used here also signals the kind of clinical risk-benefit calculus that informs protocol design for complex oncology molecules, a consideration that feeds back into process validation strategy and reference product sourcing decisions.

Where the SB27 programme sits in the broader pipeline

SB27 enters a pembrolizumab biosimilar field that includes programmes from multiple sponsors, all calibrated around Keytruda's anticipated loss of exclusivity. The competitive density of this pipeline means that regulatory submission timing and manufacturing readiness will be as consequential as clinical data quality. Samsung Bioepis has not confirmed a BLA or MAA submission date, making the Phase 3 initiation announcement the next material checkpoint for regulatory affairs leads tracking this programme.

The Phase 1 result keeps SB27 on a credible development trajectory, and the confirmatory efficacy study design, when disclosed, will indicate how Samsung Bioepis intends to navigate the extrapolation arguments central to pembrolizumab's broad oncology label.